Additive actions of the cannabinoid and neuropeptide Y systems on adiposity and lipid oxidation

Diabetes, Obesity and Metabolism

Volumn 12, Issue 7, 2010, Pages 591-603

  Zhang, L ^a   Lee, N J ^a   Nguyen, A D ^a   Enriquez, R F ^a   Riepler, S J ^a   Stehrer, B ^a   Yulyaningsih, E ^a   Lin, S ^a   Shi, Y C ^a   Baldock, P A ^a   Herzog, H ^a,b   Sainsbury, A ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Adiposity; Bone mass; CB1 receptor; Energy homeostasis; NPY

Indexed keywords

CANNABINOID 1 RECEPTOR; CORTICOSTERONE; NEUROPEPTIDE Y; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY COMPOSITION; BODY MASS; BODY WEIGHT; BONE MASS; BROWN ADIPOSE TISSUE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DIET RESTRICTION; DRUG EFFECT; DRUG MECHANISM; ENERGY METABOLISM; FOOD INTAKE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LEAN BODY WEIGHT; LIPID OXIDATION; LUNG GAS EXCHANGE; MALE; METABOLIC RATE; MOUSE; NONHUMAN; OBESITY; PHYSICAL ACTIVITY; WHITE ADIPOSE TISSUE; WILD TYPE;

EID: 77954204062     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01193.x     Document Type: Article

References (61)

1. Osei-Hyiaman D, DePetrillo M, Pacher P. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005, 115:1298-1305.
2. Engeli S, Bohnke J, Feldpausch M. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005, 54:2838-2843.
3. Cavuoto P, McAinch AJ, Hatzinikolas G, Janovska A, Game P, Wittert GA. The expression of receptors for endocannabinoids in human and rodent skeletal muscle. Biochem Biophys Res Commun 2007, 364:105-110.
4. Cota D, Marsicano G, Tschop M. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003, 112:423-431.
5. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991, 11:563-583.
6. Di Marzo V, Goparaju SK, Wang L. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001, 410:822-825.
7. Bensaid M, Gary-Bobo M, Esclango A. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003, 63:908-914.
8. Hildebrandt AL, Kelly-Sullivan DM, Black SC. Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. Eur J Pharmacol 2003, 462:125-132.
9. Ravinet-Trillou C, Arnone M, Delgorge C. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003, 284:R345-R353.
10. Herling AW, Gossel M, Haschke G. CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats. Am J Physiol Endocrinol Metab 2007, 293:E826-E832.
11. Herling AW, Kilp S, Elvert R, Haschke G, Kramer W. Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats. Endocrinology 2008, 149:2557-2566.
12. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365:1389-1397.
13. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. Jama 2006, 295:761-775.
14. Nissen SE, Nicholls SJ, Wolski K. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. Jama 2008, 299:1547-1560.
15. Liu YL, Connoley IP, Wilson CA, Stock MJ. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond) 2005, 29:183-187.
16. Gary-Bobo M, Elachouri G, Scatton B, Le Fur G, Oury-Donat F, Bensaid M. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 2006, 69:471-478.
17. Osei-Hyiaman D, Liu J, Zhou L. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 2008, 118:3160-3169.
18. Tam J, Ofek O, Fride E. Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol 2006, 70:786-792.
19. Tam J, Trembovler V, Di Marzo V. The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. Faseb J 2008, 22:285-294.
20. Takeda S, Elefteriou F, Levasseur R. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002, 111:305-317.
21. Raposinho PD, Pierroz DD, Broqua P, White RB, Pedrazzini T, Aubert ML. Chronic administration of neuropeptide Y into the lateral ventricle of C57BL/6J male mice produces an obesity syndrome including hyperphagia, hyperleptinemia, insulin resistance, and hypogonadism. Mol Cell Endocrinol 2001, 185:195-204.
22. Sainsbury A, Rohner-Jeanrenaud F, Cusin I. Chronic central neuropeptide Y infusion in normal rats: status of the hypothalamo-pituitary-adrenal axis, and vagal mediation of hyperinsulinaemia. Diabetologia 1997, 40:1269-1277.
23. Lin EJ, Sainsbury A, Lee NJ. Combined deletion of Y1, Y2 and Y4 receptors prevents hypothalamic NPY overexpression-induced hyperinsulinemia despite persistence of hyperphagia and obesity. Endocrinology 2006, 147:5094-5101.
24. Kotz CM, Briggs JE, Grace MK, Levine AS, Billington CJ. Divergence of the feeding and thermogenic pathways influenced by NPY in the hypothalamic PVN of the rat. Am J Physiol 1998, 275:R471-R477.
25. Hwa JJ, Witten MB, Williams P. Activation of the NPY Y5 receptor regulates both feeding and energy expenditure. Am J Physiol 1999, 277:R1428-R1434.
26. Stanley BG, Kyrkouli SE, Lampert S, Leibowitz SF. Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical inducer of hyperphagia and obesity. Peptides 1986, 7:1189-1192.
27. Zarjevski N, Cusin I, Vettor R, Rohner-Jeanrenaud F, Jeanrenaud B. Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity. Endocrinology 1993, 133:1753-1758.
28. Allison SJ, Baldock PA, Enriquez RF. Critical interplay between neuropeptide Y and sex steroid pathways in bone and adipose tissue homeostasis. J Bone Miner Res 2009, 24:294-304.
29. Baldock P, Lee NJ, Driessler F. Neuropeptide Y knockout mice reveal a central role of NPY in the coordination of bone mass to bone weight. PLoSOne 2009, 4:e8415.
30. Lundberg P, Allison SJ, Lee NJ. Greater bone formation of Y2 knockout mice is associated with increased osteoprogenitor numbers and altered Y1-receptor expression. J Biol Chem 2007, 282:19082-91.
31. Baldock PA, Allison SJ, Lundberg P. Novel role of Y1 receptors in the coordinated regulation of bone and energy homeostasis. J Biol Chem 2007, 282:19092-101.
32. Allison SJ, Baldock P, Sainsbury A. Conditional deletion of hypothalamic Y2 receptors reverts gonadectomy-induced bone loss in adult mice. J Biol Chem 2006, 281:23436-44.
33. Baldock PA, Sainsbury A, Couzens M. Hypothalamic Y2 receptors regulate bone formation. J Clin Invest 2002, 109:915-921.
34. Poncelet M, Maruani J, Calassi R, Soubrie P. Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice. Neurosci Lett 2003, 343:216-218.
35. Gamber KM, Macarther H, Westfall TC. Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus. Neuropharmacology 2005, 49:646-652.
36. Verty AN, Boon WM, Mallet PE, McGregor IS, Oldfield BJ. Involvement of hypothalamic peptides in the anorectic action of the CB(1) receptor antagonist rimonabant (SR 141716). Eur J Neurosci 2009, 21:21.
37. Heilig M. The NPY system in stress, anxiety and depression. Neuropeptides 2004, 38:213-224.
38. Karl T, Duffy L, Herzog H. Behavioural profile of a new mouse model for NPY deficiency. Eur J Neurosci 2008, 28:173-180.
39. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 1998, 63:PL113-PL117.
40. Zhang L, Macia L, Turner N. Peripheral neuropeptide Y Y1 receptors regulate lipid oxidation and fat accretion. Int J Obes (Lond) 2009, 17:17.
41. Ferrannini E. The theoretical bases of indirect calorimetry: a review. Metabolism 1988, 37:287-301.
42. Frayn KN. Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol 1983, 55:628-634.
43. McLean JA, Tobin G. Animal and Human Calorimetry 1987, New York, Cambridge University Press
44. Baldock PA, Sainsbury A, Allison S. Hypothalamic control of bone formation: distinct actions of leptin and y2 receptor pathways. J Bone Miner Res 2005, 20:1851-1857.
45. Patel S, Roelke CT, Rademacher DJ, Cullinan WE, Hillard CJ. Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 2004, 145:5431-5438.
46. Cota D, Steiner MA, Marsicano G. Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function. Endocrinology 2007, 148:1574-1581.
47. Jbilo O, Ravinet-Trillou C, Arnone M. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. Faseb J 2005, 19:1567-1569.
48. Henry M, Ghibaudi L, Gao J, Hwa JJ. Energy metabolic profile of mice after chronic activation of central NPY Y1, Y2, or Y5 receptors. Obes Res 2005, 13:36-47.
49. Mashiko S, Ishihara A, Iwaasa H. Characterization of neuropeptide Y (NPY) Y5 receptor-mediated obesity in mice: chronic intracerebroventricular infusion of D-Trp(34)NPY. Endocrinology 2003, 144:1793-1801.
50. Labelle M, Boulanger Y, Fournier A, St Pierre S, Savard R. Tissue-specific regulation of fat cell lipolysis by NPY in 6-OHDA-treated rats. Peptides 1997, 18:801-808.
51. Bradley RL, Mansfield JP, Maratos-Flier E. Neuropeptides, including neuropeptide Y and melanocortins, mediate lipolysis in murine adipocytes. Obes Res 2005, 13:653-661.
52. Valet P, Berlan M, Beauville M, Crampes F, Montastruc JL, Lafontan M. Neuropeptide Y and peptide YY inhibit lipolysis in human and dog fat cells through a pertussis toxin-sensitive G protein. J Clin Invest 1990, 85:291-295.
53. Castan I, Valet P, Voisin T, Quideau N, Laburthe M, Lafontan M. Identification and functional studies of a specific peptide YY-preferring receptor in dog adipocytes. Endocrinology 1992, 131:1970-1976.
54. Serradeil-Le Gal C, Lafontan M, Raufaste D. Characterization of NPY receptors controlling lipolysis and leptin secretion in human adipocytes. FEBS Lett 2000, 475:150-156.
55. Castan I, Valet P, Quideau N. Antilipolytic effects of alpha 2-adrenergic agonists, neuropeptide Y, adenosine, and PGE1 in mammal adipocytes. Am J Physiol 1994, 266:R1141-R1147.
56. Turner N, Bruce CR, Beale SM. Excess lipid availability increases mitochondrial fatty acid oxidative capacity in muscle: evidence against a role for reduced fatty acid oxidation in lipid-induced insulin resistance in rodents. Diabetes 2007, 56:2085-2092.
57. Sanofi-Aventis to Discontinue All Clinical Trials with Rimonabant 2008, Paris
58. Doyon C, Denis RG, Baraboi ED. Effects of rimonabant (SR141716) on fasting-induced hypothalamic-pituitary-adrenal axis and neuronal activation in lean and obese Zucker rats. Diabetes 2006, 55:3403-3410.
59. Konno J, Yoshida S, Ina A. Upregulated expression of neuropeptide Y in hypothalamic-pituitary system of rats by chronic dexamethasone administration. Neurosci Res 2008, 60:259-265.
60. Shimizu H, Arima H, Watanabe M. Glucocorticoids increase neuropeptide Y and agouti-related peptide gene expression via adenosine monophosphate-activated protein kinase signaling in the arcuate nucleus of rats. Endocrinology 2008, 149:4544-4553.
61. Sainsbury A, Schwarzer C, Couzens M. Important role of hypothalamic Y2 receptors in body weight regulation revealed in conditional knockout mice. Proc Natl Acad Sci U S A 2002, 99:8938-8943.